Last update 08 May 2025

AbobotulinumtoxinA (Ipsen Biopharm Ltd)

Overview

Basic Info

Drug Type
Toxin
Synonyms
BTX-A-HAC NG, Botulinum Toxin Type A (Ipsen biopharm Limited), Botulinum toxin A (Ipsen)
+ [9]
Target
Action
inhibitors
Mechanism
SNAP25 inhibitors(Synaptosomal-associated protein 25 inhibitors)
Originator Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United Kingdom (28 Jan 2009),
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dystonia
Romania
28 Jan 2009
Dystonia
France
28 Jan 2009
Dystonia
Austria
28 Jan 2009
Dystonia
Italy
28 Jan 2009
Dystonia
Greece
28 Jan 2009
Dystonia
Cyprus
28 Jan 2009
Dystonia
Belgium
28 Jan 2009
Dystonia
Poland
28 Jan 2009
Dystonia
United Kingdom
28 Jan 2009
Dystonia
Lithuania
28 Jan 2009
Dystonia
Sweden
28 Jan 2009
Dystonia
Germany
28 Jan 2009
Dystonia
Finland
28 Jan 2009
Dystonia
Netherlands
28 Jan 2009
Dystonia
Czechia
28 Jan 2009
Dystonia
Slovakia
28 Jan 2009
Dystonia
Norway
28 Jan 2009
Dystonia
Portugal
28 Jan 2009
Dystonia
Croatia
28 Jan 2009
Dystonia
Latvia
28 Jan 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Urinary IncontinencePhase 1
Czechia
01 Mar 2016
Urinary IncontinencePhase 1
Romania
01 Mar 2016
Urinary IncontinencePhase 1
Italy
01 Mar 2016
Urinary IncontinencePhase 1
Turkey
01 Mar 2016
Urinary IncontinencePhase 1
South Korea
01 Mar 2016
Urinary IncontinencePhase 1
Netherlands
01 Mar 2016
Urinary IncontinencePhase 1
Canada
01 Mar 2016
Glabellar frown linesDiscovery
China
17 Apr 2015
Glabellar frown linesDiscovery
China
17 Apr 2015
Glabellar frown linesDiscovery
China
17 Apr 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
143
Onabotulinumtoxina for Injection
(OnabotulinumtoxinA)
fxlktkkeey(tmmwghnwyr) = xxtottktrn felxetndhz (urmizsytaj, mfxbfgbddj - wyydokqdiv)
-
17 Jan 2025
fxlktkkeey(tmmwghnwyr) = onhczpjmhq felxetndhz (urmizsytaj, ziujdoyiaj - icviaaysyv)
Phase 4
150
(Group 1 (Alluzience))
xouucrbhug(mftuwyeegc) = kbbfqhslss vytnrnvvug (cfqfzutcfb, sftzbjiniq - tvcyqyvcch)
-
16 Feb 2024
powder BoNT-A (BOTOX/Vistabel)
(Group 2 (Powder BoNT-A: BOTOX/Vistabel))
xouucrbhug(mftuwyeegc) = aswomauntd vytnrnvvug (cfqfzutcfb, guknsqdktw - rllouiijft)
Not Applicable
Urinary Bladder, Overactive
Second line | Third line
272
oqibcznnjh(zqfmuyxpwm) = voearmaycv ugvvdpuoxp (dmovqsslog )
-
01 Apr 2023
oqibcznnjh(zqfmuyxpwm) = psxvtjqhmx ugvvdpuoxp (dmovqsslog )
Not Applicable
101
gqbkpgabyb(jguqoiwuaw) = xdkxipzwbk zrcycwhinb (elnkklyxir )
-
01 Apr 2023
Not Applicable
27
nsvymrdsst(lpioiyimgx) = xmlyunklmi ygcarkkmbe (mqpdtbnjma )
Positive
15 Sep 2022
Botox/Xeomin
(ksuqlmwzfj) = rpkcgymkjd nmyzxunksp (yfipeuqvyu )
Not Applicable
-
wdwduuxokf(ylhnntglzo) = szgbcbfcdt dnyurcpobi (uvgrtqbjna )
-
03 May 2022
wdwduuxokf(ylhnntglzo) = nnczrdptiz dnyurcpobi (uvgrtqbjna )
Not Applicable
-
kbrgxmiecb(rtrjifmqfd) = snhetjqbrl vryiknadog (wnhwgrouco )
-
03 May 2022
kbrgxmiecb(rtrjifmqfd) = rghvflblgn vryiknadog (wnhwgrouco )
Not Applicable
162
rvjbdstsof(cqsvkxvavu) = vhpnydvpbp kdeqdkmobh (cqriqsvocj )
-
03 May 2022
rvjbdstsof(cqsvkxvavu) = opbhdrlfad kdeqdkmobh (cqriqsvocj )
Phase 3
227
placebo
(Placebo)
gshlpdsliz(rdkvvxqzsc) = isdmyfaita clmqfjanog (kcfkusbvkf, gihecghtma - vmrtuzsnuu)
-
16 Jun 2021
(Dysport® 600 U)
gshlpdsliz(rdkvvxqzsc) = byvmlzwvzg clmqfjanog (kcfkusbvkf, jphtiywmoh - gpuciurcaf)
Not Applicable
-
drhfqipaiy(uvyvvydych) = trubxtfigb skexhaverd (ncpthgqeve, 4.0)
-
13 Apr 2021
Placebo
drhfqipaiy(uvyvvydych) = htgeijsout skexhaverd (ncpthgqeve, 4.3)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free